Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AIPAC (Active Immunotherapy PAClitaxel): A Multicentre, Phase IIb, Randomised,Double Blind, Placebo-controlled Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients Receiving IMP321 (LAG-3Ig Fusion Protein) or Placebo as Adjunctive to a Standard Chemotherapy Treatment Regimen of Paclitaxel

Next Previous
Search
Trial Profile

AIPAC (Active Immunotherapy PAClitaxel): A Multicentre, Phase IIb, Randomised,Double Blind, Placebo-controlled Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients Receiving IMP321 (LAG-3Ig Fusion Protein) or Placebo as Adjunctive to a Standard Chemotherapy Treatment Regimen of Paclitaxel

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eftilagimod alpha (Primary) ; Paclitaxel
  • Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms AIPAC
  • Sponsors Immutep

    • Most Recent Events

    • 08 Nov 2023 Primary endpoint has not been met. (Assessment of Progression-Free Survival (PFS))
    • 08 Nov 2023 Results published in the Clinical Cancer Research
    • 04 May 2022 According to an Immutep Limited media release, new biomarker and multivariate analysis data from this study was presented at the ESMO's Breast Cancer Congress 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top